Compared side by side
KPV vs LL-37: how they differ
The short answer
KPV is three amino acids from the tail end of α-MSH; in cell and mouse studies it enters cells and blocks NF-κB, the master switch for inflammatory signals. LL-37 is the body’s own antimicrobial peptide: in lab studies it kills bacteria, fungi and some viruses and steers immune responses, and it can be anti- or pro-inflammatory depending on context. No human study has tested KPV, and LL-37 has been tested as a drug only as a topical treatment for leg and foot ulcers.
Side by side
| Compared | KPV | LL-37 |
|---|---|---|
| Category | Healing & recovery | Healing & recovery |
| Also known as | Lys-Pro-Val, α-MSH tripeptide | Cathelicidin, hCAP-18, CAP-18 |
| What it is | One of the smallest bioactive peptides: three amino acids from the tail end of α-MSH. | Your body's own antimicrobial peptide. |
| How it works | C-terminal tripeptide of α-MSH. A potent anti-inflammatory in cell and mouse studies that works mainly inside cells rather than through melanocortin receptors: it enters through the PepT1 transporter and blocks NF-κB signaling. In mice it eased colitis and damped allergic skin reactions; as eye drops it sped corneal wound healing in rabbits; in lab dishes it slowed Staphylococcus aureus and Candida albicans. | Human antimicrobial peptide with broad-spectrum antimicrobial activity. In lab and animal studies it modulates innate immunity, breaks up biofilms and promotes wound healing; it can be anti- or pro-inflammatory depending on context. |
| Commonly reported | A calmer gut and calmer skin. No human study has tested it yet. | Noticeable injection-site redness or itching, and for some a flu-like, achy feeling in the first days. As a drug it has only been tested as a topical treatment for leg and foot ulcers, with mixed results; injected LL-37 hasn't been studied in people. |
| Studied range | Research range: 100–300 mcg. Studied in research — not a recommendation. | Research range: 100–300 mcg. Studied in research — not a recommendation. |
| How often | Daily | Daily or EOD |
| Half-life | Not measured: no half-life for KPV has been published, in people or animals | Unknown in humans (short; broken down by proteases) |
| Route | SubQ injection, Oral | SubQ injection |
| Typical run | 4–8 weeks typical for gut protocols. Can reassess after each cycle. | Short cycles of 2–4 weeks due to limited data. Conservative approach advised. |
| Evidence | Emerging: primarily preclinical / limited human data | Emerging: primarily preclinical / limited human data |
| Common side effects | Injection site irritation, mild nausea | Injection site pain, redness, mild systemic inflammation |
- Category
- KPVHealing & recovery
- LL-37Healing & recovery
- Also known as
- KPVLys-Pro-Val, α-MSH tripeptide
- LL-37Cathelicidin, hCAP-18, CAP-18
- What it is
- KPVOne of the smallest bioactive peptides: three amino acids from the tail end of α-MSH.
- LL-37Your body's own antimicrobial peptide.
- How it works
- KPVC-terminal tripeptide of α-MSH. A potent anti-inflammatory in cell and mouse studies that works mainly inside cells rather than through melanocortin receptors: it enters through the PepT1 transporter and blocks NF-κB signaling. In mice it eased colitis and damped allergic skin reactions; as eye drops it sped corneal wound healing in rabbits; in lab dishes it slowed Staphylococcus aureus and Candida albicans.
- LL-37Human antimicrobial peptide with broad-spectrum antimicrobial activity. In lab and animal studies it modulates innate immunity, breaks up biofilms and promotes wound healing; it can be anti- or pro-inflammatory depending on context.
- Commonly reported
- KPVA calmer gut and calmer skin. No human study has tested it yet.
- LL-37Noticeable injection-site redness or itching, and for some a flu-like, achy feeling in the first days. As a drug it has only been tested as a topical treatment for leg and foot ulcers, with mixed results; injected LL-37 hasn't been studied in people.
- Studied range
- KPVResearch range: 100–300 mcg. Studied in research — not a recommendation.
- LL-37Research range: 100–300 mcg. Studied in research — not a recommendation.
- How often
- KPVDaily
- LL-37Daily or EOD
- Half-life
- KPVNot measured: no half-life for KPV has been published, in people or animals
- LL-37Unknown in humans (short; broken down by proteases)
- Route
- KPVSubQ injection, Oral
- LL-37SubQ injection
- Typical run
- KPV4–8 weeks typical for gut protocols. Can reassess after each cycle.
- LL-37Short cycles of 2–4 weeks due to limited data. Conservative approach advised.
- Evidence
- KPVEmerging: primarily preclinical / limited human data
- LL-37Emerging: primarily preclinical / limited human data
- Common side effects
- KPVInjection site irritation, mild nausea
- LL-37Injection site pain, redness, mild systemic inflammation
Typical run: Community practice — opinions vary. Not a clinical recommendation.

Week by week
Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.
KPV
- Day 1–7 Week one: your starting point
- Day 7–21 Users often report a calmer gut
- Day 21–42 Some report calmer skin
- Day 42–56 Weeks 6 to 8: taking stock
LL-37
- Day 1–7 Some feel a flu-like wave early
- Day 7–21 Weeks 1 to 3: check what changed
- Day 21–28 Cycle wrap-up — time to assess
Together or one or the other
KPV and LL-37 are a common stack: each lists the other among its common stacks.
Community · LL-37
An immune-support trio
Three immune layers at once: LL-37 works on microbes directly, KPV calms inflammation, and thymosin alpha-1 tunes the adaptive side. Commonly stacked for immune support; users judge it by how they feel over several weeks.
Questions people ask
How long do KPV and LL-37 last?
The half-life of KPV is not measured: no half-life for KPV has been published, in people or animals. The half-life of LL-37 is unknown in humans (short; broken down by proteases).
How often are KPV and LL-37 taken?
KPV: daily. Routes: SubQ injection, oral. LL-37: daily or EOD. Route: SubQ injection.
How are KPV and LL-37 dosed in research?
The research range for KPV is 100–300 mcg. The research range for LL-37 is 100–300 mcg. Studied in research — not a recommendation.
What are the common side effects of KPV and LL-37?
For KPV, the library lists: injection site irritation, mild nausea. For LL-37: injection site pain, redness, mild systemic inflammation.
Are KPV and LL-37 taken together?
KPV and LL-37 are a common stack: each lists the other among its common stacks. Three immune layers at once: LL-37 works on microbes directly, KPV calms inflammation, and thymosin alpha-1 tunes the adaptive side. Commonly stacked for immune support; users judge it by how they feel over several weeks.